3 news items
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
ELTX
10 Jun 24
company focused on developing innovative lymph node-targeted immunotherapies to treat aggressive cancers. Given the firm's expertise in materials
Elicio Therapeutics Celebrates 13 Years Developing Innovative Cancer Immunotherapies
ELTX
24 Apr 24
breakthroughs. Immunotherapy, a specific niche within biotechnology, also represents the forefront of medical innovation. As the number
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
ELTX
11 Apr 24
developed an innovative pipeline of cancer immunotherapies with the potential to address critical unmet needs, with three vaccine candidates currently
- Prev
- 1
- Next